VITALOrigin
In Frankreich gemeldetes Nahrungsergänzungsmittel, Meldung Nr. 2019-3-693, Entscheidung vom 14. März 2019
VITALOrigin (3C Pharma) ist ein in Frankreich gemeldetes Nahrungsergänzungsmittel. Status: in Frankreich gemeldet, Inverkehrbringen möglich. Keine unserer geprüften Vorschriften ergibt einen Prüfpunkt zur deklarierten Zusammensetzung; Vitamin- und Mineralstoffdosen werden von Compl’Alim nicht veröffentlicht und deshalb nicht kontrolliert.
- Marke
- 3C Pharma
- Für das Inverkehrbringen verantwortlich
- LES TROIS CHENES
- Status
- In Frankreich gemeldet, Inverkehrbringen möglich: Die Verwaltung hat der Meldung nicht widersprochen (weder Zulassung noch Sicherheitsbewertung)
- Form
- Tablette
- Tagesdosis
2
- Gebrauchsanweisung
Übersetzung nicht verfügbar. Originaltext, Sprache: Französisch.
Prendre 2 comprimés par jour avec un verre d’eau.
- Nicht empfohlen (laut Hersteller)
- Schwangere, Einnahme von Medikamenten, Einnahme von Schilddrüsenmedikamenten
- Vom Hersteller angegebene Ziele (keine zugelassenen gesundheitsbezogenen Angaben)
- Verdauung
Meldung 294255, Verfahren Article 16. Compl’Alim, Meldungen von Nahrungsergänzungsmitteln, abgerufen am 15. November 2026.
Deklarierte Zusammensetzung
Pflanzen
| Pflanze | Teil | Zubereitung | Täglich |
|---|---|---|---|
| Rosmarinus officinalis L. | Feuille | Extrait sec aqueux | 334 mg |
| Silybum marianum (L.) Gaertn. | Graine | Autre extrait sec | 250 mg |
| Hypericum perforatum L. | Fleur | Extrait sec hydroalcoolique | 200 mg |
| Tilia × europaea L. | Fleur | Extrait sec aqueux | 100 mg |
| Desmodium adscendens (Sw.) DC. | Feuille | Extrait sec hydroalcoolique | 60 mg |
| Citrus paradisi Macfad. | Graine | Extrait sec hydroalcoolique | 20 mg |
| Cynara scolymus L. | Feuille | Extrait sec aqueux | 8,33 mg |
| Raphanus raphanistrum subsp. sativus (L.) Domin | Racine | Poudre (de plantes séchées ou broyées) | 5 mg |
Weitere aktive Inhaltsstoffe
| Name | Täglich |
|---|---|
| Citrate de choline | nicht gemeldet |
| Bétaïne | nicht gemeldet |
| Acétylcystéine | nicht gemeldet |
| Bromélaïne | nicht gemeldet |
Vitamine und Mineralstoffe
Compl’Alim veröffentlicht keine Vitamin- und Mineralstoffdosen. Die folgenden Referenzwerte helfen, das Etikett zu lesen: sicherer Zufuhrwert der EFSAEuropäische Behörde für Lebensmittelsicherheit. für Erwachsene und französische Höchstdosis je Produkt (Erlass vom 9. Mai 2006, seit November 2006 nicht überarbeitet).
| Deklarierte Verbindung | Nährstoff | EFSA-Grenzwert, Erwachsene | Höchstdosis in Frankreich |
|---|---|---|---|
| Sélénite de sodium | Sélénium | 255 µg | 50 µg |
| Acétate de DL-alpha-tocophéryle | Vitamine E | 300 mg | 30 mg |
Zusatzstoffe
E460, E470b, E341
Weitere Inhaltsstoffe
poudre de citron
Liste aus der Meldung, behördliche Entscheidung vom (Compl’Alim, Meldungen von Nahrungsergänzungsmitteln).
Rechtliche Prüfpunkte
Keine der von uns geprüften Vorschriften gilt für die gemeldeten Inhaltsstoffe.
Diese Angaben geben die Meldung des Herstellers bei der Verwaltung (DGAL) wieder. Sie besagen nicht, ob das Produkt wirksam ist, und ersetzen keinen ärztlichen oder pharmazeutischen Rat, insbesondere während Schwangerschaft oder medikamentöser Behandlung.
Offizielle Warnhinweise (Health Canada)
Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:
- Rosmarinus officinalis L.
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Art der Anwendung: Oral (ESCOP 2003)
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Monografie von Health Canada vom 29. Mai 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Art der Anwendung: Topical (ESCOP 2003)
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
Von Health Canada zitierte Quellen (1)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Bekannte Nebenwirkungen
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Silybum marianum (L.) Gaertn.
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
MILK THISTLE - SILYBUM MARIANUM
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Von Health Canada zitierte Quellen (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Bekannte Nebenwirkungen
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Von Health Canada zitierte Quellen (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
- Hypericum perforatum L.
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
ST. JOHN'S WORT -HYPERICUM PERFORATUM- Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005).
Von Health Canada zitierte Quellen (3)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; Kawaguchi et al. 2004; Morimoto et al. 2004; Eich-Höchli et al. 2003; Dresser et al. 2003; Hoffman 2003; Markowitz et al. 2003; Xie et al. 2003; Dannawi 2002; Gurley et al. 2002; Spinella and Eaton 2002; Wang et al. 2002; Parker et al. 2001; Wang et al. 2001; Burstein et al. 2000; Nebel et al. 1999).
Von Health Canada zitierte Quellen (17)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. 2000. Lack of effect of St John's Wort on carbazepine pharmacokinetics in healthy volunteers. Clinical Pharmacology and Therapeutics 68(6):605-612.
- Dannawi M. 2002. Possible serotonin syndrome after combination of buspirone and St John's wort. Journal of Psychopharmacology 16(4):401.
- Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
- Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. 2003. Methadone maintenance treatment and St John's wort: a case report. Pharmacopsychiatry 36(1):35-37.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. 2002. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacology and Therapeutics 72(3):276-287.
- Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. 2004. Drug interaction between St John's Wort and quazepam. British Journal of Clinical Pharmacology 58(4):403-410.
- Markowitz JS, Donovan JL, DeVane CL, Talor RM, Ruan Y, Wang J, Chavin KD. 2003. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. The Journal of the American Medical Association. 290(11):1500-1504.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
- Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. 2004. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. Journal of Clinical Pharmacology 44(1):95-101.
- Nebel A, Schneider BJ, Baker RK, Kroll DJ. 1999. Potential metabolic interaction between St. John's wort and theophylline. The Annals of Pharmacotherapy 33(4):502.
- Parker V, Wong AH, Boon HS, Seeman MV. 2001. Adverse reactions to St John's wort. Canadian Journal of Psychiatry 46(1):77-79.
- Spinella M, Eaton LA. 2002. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Injury 16(4):359-367.
- Wang ZQ, Hamman MA, Huang SM, Lesko LJ, Hall SD. 2002. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clinical Pharmacology and Therapeutics 71(6):414-420.
- Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
- Xie R, Tan L, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ. 2003. CYP3A and P-glycoprotein induction with St. John's wort in healthy volunteers of selected ethnic populations. Journal of Clinical Pharmacology 45(3):352-356.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; ESCOP 2003; Hoffmann 2003; McGuffin et al. 1997).
Von Health Canada zitierte Quellen (6)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. 1997. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Bilia et al. 2002; Ernst et al. 1998).
Von Health Canada zitierte Quellen (2)
- Bilia AR, Gallori S, Vincieri FF. St John's wort and depression: efficacy, safety and tolerability - an update. Life Sciences 2002;70(26):3077-3096. PubMed Übersichtsartikel
- Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). European Journal of Clinical Pharmacology 1998;54:589-594. PubMed Systematische Übersicht
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Do not use if you are taking antidepressants, anxiolytics, anti-cancer, cardiovascular, contraceptive medications, blood thinners, anti-HIV agents and/or medications to suppress the immune system (Brinker 2010; Barnes et al. 2007; Bradley 2006; Mills and Bone 2005; Murphy et al. 2005; Frye et al. 2004; Hebert et al. 2004; Jiang et al. 2004; Mueller et al. 2004; Smith et al. 2004; Sparreboom et al. 2004; Tannergren et al. 2004; Wichtl 2004; Alscher and Klotz 2003; Bauer et al. 2003; Dresser et al. 2003; ESCOP 2003; Hall et al. 2003; Hoffmann 2003; Pfrunder et al. 2003; Schwarz et al. 2003; Bolley 2002; Gorski et al. 2002; Mathijssen et al. 2002; Ahmed et al. 2001; De Maat et al. 2001; Moschella and Jaber 2001; Roby et al. 2001; Sugimoto et al. 2001; Turton-Weeks 2001; Wang et al. 2001; Barone et al. 2000; Durr et al. 2000; Karliova et al. 2000; Mai et al. 2000; Piscitelli et al. 2000; Ruschitzka et al. 2000; Ernst 1999; Johne et al. 1999; Maurer et al. 1999; Rey and Walter 1998).
Von Health Canada zitierte Quellen (41)
- Ahmed SM, Banner NR, Dubrey SW. 2001. Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. Journal of Heart and Lung Transplantation 20(7):795.
- Alscher DM, Klotz U. 2003. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transplant International 16(7):543-544.
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2000. Drug interaction between St. John's wort and cyclosporine. The Annals of Pharmacotherapy 34(9):1013-1016.
- Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, Roots I, Mai I. 2003. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. British Journal of Clinical Pharmacology 55(2):203-211.
- Bolley R, Zülke C, Kammerl M, Fischereder M, Krämer BK. 2002. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 73(6):1009.
- Bradley PR, editor. 2006. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- De Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. 2001. Drug interaction between St John's wort and nevirapine. AIDS 15(3):420-421.
- Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
- Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. 2000.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Ernst E. 1999. Second thoughts about the safety of St. John's wort. Lancet 354(9195):20142016.
- Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. 2004. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics 76(4):323-329.
- Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. 2002. The effect of St John's wort on the efficacy of oral contraception. Clinical Pharmacology and Therapeutics 71:P25.
- Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. 2003. The interaction between St. John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics 74(6):525-535.
- Hebert MF, Park JM, Chen YL, Akhatar S, Larson AM. 2004. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 44(1):89-94.
- Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
- Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. 2004. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology 57(5):592-599.
- Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich, M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics 66(4):338-345.
- Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. 2000. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. Journal of Hepatology 33(5):853-855.
- Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH, Roots I. 2000. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. International Journal of Clinical Pharmacology and Therapeutics 38(10):500-502.
- Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. 2002. Effects of St John's wort on irinotecan metabolism. Journal of the National Cancer Institute 94(16):1247-1249.
- Maurer A, Johne A, Bauer S, Brockmoller F, Conath I, Roots M, Langheinrich M, Hubner WD. 1999. Interaction of St. John's wort extract with phenprocoumon [Abstract]. European Journal of Clinical Pharmacology 55:A22.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
- Moschella C, Jaber BL. 2001. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. American Journal of Kidney Diseases 38(5):1105-1107.
- Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. 2004. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clinical Pharmacology and Therpeutics 75(6):546-557.
- Murphy A, Kern SE, Stanczyk FZ, Westhoff CL. 2005. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71(6):402-408.
- Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. 2003. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. British Journal of Clinical Pharmacology 56(6):683-690.
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355(9203):547-548.
- Rey JM, Walter G. 1998. Hypericum perforatum (St John's wort) in depression: pest or blessing? The Medical Journal of Australia 169(11-12):583-586.
- Roby CA, Dryer DA, Burstein AH. 2001. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. Journal of Clinical Psychopharmacology 21(5):530-532.
- Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355(9203):548-549.
- Schwarz UI, Büschel B, Kirch W. 2003. Unwanted pregnancy on self- medication with St John's wort despite hormonal contraception. British Journal of Clinical Pharmacology 55(1):112-113.
- Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. 2004. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24(11):1508-1514.
- Sparreboom A, Cox MC, Acharya MR, Figg WD. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. Journal of Clinical Oncology 22(12):2489-2503.
- Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. 2001. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clinical Pharmacology and Therapeutics 70(6):518-524.
- Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. 2004. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clinical Pharmacology and Therapeutics 75(4):298-309.
- Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2001. St John's wort: a hidden risk for transplant patients. Progress in Transplantation 11(2):116-120.
- Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
- Wichtl M, editor. 2004. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis, 3rd edition. Stuttgart (D): Medpharm GmbH Scientific Publishers.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Bekannte Nebenwirkungen
When using this product you may experience mild gastrointestinal disturbances, restlessness, and/or headaches (Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (2)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience muscle rigidity or contractions, tremors, agitation/confusion, increased heart rate, or hypersensitivity/allergy (Boyer 2023; Mayo Clinic Staff 2022; Erner et al. 2003; Papakostas et al. 2007; Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (6)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Boyer EW. Liebelt EL, Ganetsky M. 2023. Serotonin syndrome (serotonin toxicity). UpToDate. [Accessed 2023 September 11]. Available from: https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. 2003. Serotonin Syndrome and Other Serotonergic Disorders, Pain Medicine, Volume 4, Issue 1, Pages 63-74.
- Mayo Clinic Staff. 2022. Persistent depressive disorder. Mayo Clinic. [Accessed 2023 September 11]. Available from : https://www.mayoclinic.org/diseases-conditions/persistent-depressive-disorder/diagnosis-treatment/drc-20350935
- Papakostas GI, Crawford CM, Scalia MJ, Fava M. 2007. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 56(2-3):132-137.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Monografie von Health Canada vom 26. Juli 2024
ST. JOHN'S WORT - HYPERICUM PERFORATUM - Topical
Vorsichtsmaßnahmen und Warnhinweise
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Gegenanzeigen
Do not use on deep or puncture wounds, animal bites or serious burns.
- Bétaïne
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
BETAINE / BETAINE HYDROCHLORIDE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Gilt für Produkte: containing Betaine hydrochloride (as a medicinal ingredient or as a source ingredient).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a peptic ulcer or excess stomach acid (RSC 2024; Hendler and Rorvik 2008).
Von Health Canada zitierte Quellen (2)
- Hendler SS, Rorvik DM. PDR® for Nutritional Supplements, 2nd edition. Thomson Reuters. Physicians' Desk References Inc., NJ; 2008.
- RSC 2024: Royal Society of Chemistry: The Merck Index Online [Accessed 2024 June 20]. Available from: https://merckindex.rsc.org/
Gilt für Produkte: providing 600 milligrams or more of Betaine or 780 milligrams or more of Betaine hydrochloride as a medicinal ingredient, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high cholesterol (Olthof et al. 2005; Swab et al. 2002).
Von Health Canada zitierte Quellen (2)
- Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in health humans. PLoS Medicine 2005;2(5):e135. PubMed Randomisierte Studie
- Swab U, Torronen A, Toppinen L, Alfthan G, Saarinen M, Aro A, Uusitupa M. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. American Journal of Clinical Nutrition 2002;76:961-967.
- Acétylcystéine
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
N-ACETYL-L-CYSTEINE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).
Von Health Canada zitierte Quellen (2)
- Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
- Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed
Gegenanzeigen
Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).
Von Health Canada zitierte Quellen (4)
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomisierte Studie
- Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Übersichtsartikel
- Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
- Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.
Marke : 3C Pharma
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.